<DOC>
	<DOCNO>NCT00695292</DOCNO>
	<brief_summary>This propose Phase II trial investigate combination irinotecan carboplatin follow sunitinib first-line treatment patient extensive-stage SCLC .</brief_summary>
	<brief_title>Irinotecan , Carboplatin , Sunitinib First Line Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>Irinotecan/platinum regimens emerge standard treatment patient extensive-stage disease . The irinotecan/carboplatin dos use study use two previous Phase II SCLC trial , find extremely well tolerate ( Thompson et al . 2005 ; Spigel et al . 2007 ) . Adding novel , minimally toxic agent regimen may enhance efficacy patient population without contribute toxicity . This trial evaluate use sunitinib follow 6 cycle treatment chemotherapy treatment SCLC . The trial perform leadership SCRI , community-based , multi-center , clinical trial organization .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Cytologically and/or histologically confirm smallcell lung cancer extensivestage disease . 2 . Measurable evaluable disease . 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . 4 . Adequate bone marrow function , define : absolute neutrophil count ( ANC ) &gt; 1,500/µL ; platelet &gt; 100,000/µL ; hemoglobin &gt; =9.0 g/dL . 5 . Normal organ function , define follow : aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; =2.5 × upper limit normal ( ULN ) , AST ALT &lt; =5 × ULN liver function abnormality due underlying malignancy ; total serum bilirubin &lt; =1.5 × ULN ; serum creatinine &lt; =1.5 × ULN . 6 . Resolution acute toxic effect prior therapy surgical procedure grade &lt; =1 . 7 . Women childbearing potential men partner childbearing potential must agree use form birth control acceptable physician prevent pregnancy treatment . 8 . Patients must inform investigational nature study sign inform consent form . 9 . Patients treat brain metastasis &gt; =4 week ( surgery and/or radiation therapy ) evidence central nervous system ( CNS ) progression . Steroid use discontinue study treatment begin . 1 . Patients pregnant breastfeeding . 2 . Patients may receive agent ( either investigational market ) act antiangiogenic mechanism . Angiogenesis inhibitor include ( limited ) : thalidomide , sorafenib , bevacizumab . 3 . Patients previous chemotherapy radiation therapy extensivestage disease exclude . Palliative radiation ( e.g. , bone disease ) radiation cranial metastasis acceptable patient recover adverse effect . 4 . Previous treatment sunitinib . 5 . Myocardial infarction , severe unstable angina , coronary/peripheral artery bypass graft , congestive heart failure ( CHF ) , cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism within 6 month prior study initiation . 6 . Ongoing cardiac dysrhythmias National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) grade &gt; =2 , atrial fibrillation grade , prolongation QTc interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) . 7 . Uncontrolled hypertension ( i.e. , blood pressure &gt; 150 mm Hg control standard antihypertensive agent ) . 8 . Active brain metastasis . ( Patients brain metastasis treat radiation surgery evidence progressive brain metastasis least 4 week later eligible ) . 9 . Patients major surgical procedure , open biopsy , significant traumatic injury 28 day ( 4 week ) study initiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Extensive Stage</keyword>
	<keyword>irinotecan</keyword>
	<keyword>carboplatin</keyword>
	<keyword>sunitinib</keyword>
</DOC>